vs
Side-by-side financial comparison of FIRST HAWAIIAN, INC. (FHB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
FIRST HAWAIIAN, INC. is the larger business by last-quarter revenue ($220.3M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). FIRST HAWAIIAN, INC. runs the higher net margin — 30.8% vs 1.6%, a 29.1% gap on every dollar of revenue. Over the past eight quarters, FIRST HAWAIIAN, INC.'s revenue compounded faster (3.8% CAGR vs -0.2%).
First Hawaiian, Inc. is a bank holding company headquartered in Honolulu, Hawaiʻi. Its principal subsidiary, First Hawaiian Bank, founded in 1858, is Hawaiʻi’s oldest and largest financial institution headquartered in Honolulu at the First Hawaiian Center. The bank has 57 branches throughout Hawaiʻi, three in Guam and one in Saipan. It offers banking services to consumer and commercial customers, including deposit products, lending services and wealth management, insurance, private banking an...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FHB vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $220.3M | $177.4M |
| Net Profit | $67.8M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 30.8% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | 14.4% | — |
| EPS (diluted) | $0.55 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $220.3M | $177.4M | ||
| Q4 25 | $225.9M | $196.9M | ||
| Q3 25 | $226.4M | $179.5M | ||
| Q2 25 | $217.5M | $181.1M | ||
| Q1 25 | $211.0M | $168.9M | ||
| Q4 24 | $188.1M | $187.3M | ||
| Q3 24 | $210.0M | $168.6M | ||
| Q2 24 | $204.6M | $178.0M |
| Q1 26 | $67.8M | $2.9M | ||
| Q4 25 | $69.9M | — | ||
| Q3 25 | $73.8M | $5.4M | ||
| Q2 25 | $73.2M | $-4.8M | ||
| Q1 25 | $59.2M | $4.8M | ||
| Q4 24 | $52.5M | — | ||
| Q3 24 | $61.5M | $-143.5M | ||
| Q2 24 | $61.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 41.2% | 1.2% | ||
| Q3 25 | 42.5% | 3.5% | ||
| Q2 25 | 40.5% | 4.7% | ||
| Q1 25 | 36.5% | 1.2% | ||
| Q4 24 | 34.4% | 13.2% | ||
| Q3 24 | 36.4% | -82.8% | ||
| Q2 24 | 39.5% | 15.9% |
| Q1 26 | 30.8% | 1.6% | ||
| Q4 25 | 31.0% | — | ||
| Q3 25 | 32.6% | 3.0% | ||
| Q2 25 | 33.7% | -2.7% | ||
| Q1 25 | 28.1% | 2.8% | ||
| Q4 24 | 27.9% | — | ||
| Q3 24 | 29.3% | -85.1% | ||
| Q2 24 | 30.3% | 10.6% |
| Q1 26 | $0.55 | $0.07 | ||
| Q4 25 | $0.56 | $0.05 | ||
| Q3 25 | $0.59 | $0.12 | ||
| Q2 25 | $0.58 | $-0.11 | ||
| Q1 25 | $0.47 | $0.10 | ||
| Q4 24 | $0.41 | $0.38 | ||
| Q3 24 | $0.48 | $-3.11 | ||
| Q2 24 | $0.48 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $2.8B | $653.9M |
| Total Assets | $24.3B | $1.2B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | $0 | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.8B | $653.9M | ||
| Q4 25 | $2.8B | $693.1M | ||
| Q3 25 | $2.7B | $727.2M | ||
| Q2 25 | $2.7B | $757.8M | ||
| Q1 25 | $2.6B | $798.5M | ||
| Q4 24 | $2.6B | $778.3M | ||
| Q3 24 | $2.6B | $749.6M | ||
| Q2 24 | $2.6B | $879.3M |
| Q1 26 | $24.3B | $1.2B | ||
| Q4 25 | $24.0B | $1.3B | ||
| Q3 25 | $24.1B | $1.3B | ||
| Q2 25 | $23.8B | $1.5B | ||
| Q1 25 | $23.7B | $1.6B | ||
| Q4 24 | $23.8B | $1.6B | ||
| Q3 24 | $23.8B | $1.5B | ||
| Q2 24 | $24.0B | $1.6B |
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHB
| Net Interest Income | $167.5M | 76% |
| Noninterest Income | $52.8M | 24% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
